Aspirin remains the mainstay of therapy of rheumatoid arthritis (RA), but many patients become intolerant of therapeutically effective doses while a few become anaemic from symptomless gastrointestinal bleeding. The search continues for new agents as effective as aspirin with fewer side-effects.
Many of the non-hormonal anti-inflammatory agents are aryl esters and aryl-substituted phenols and enols (Harrison, Lewis, Nelson, Rooks, Roskowski, Tomolonis, and Fried, 1970) . It is possible that some serious adverse reactions, such as blood dyscrasias, liver damage and psychic disturbance, are specifically associated with those non-hormonal anti-inflammatory agents containing nitrogen (Harrison and others, 1970) . If this hypothesis is correct, non-nitrogen-containing aryl acids might be expected to retain the advantages of this type of compound while minimizing the potential for such adverse reactions.
Of over 200 compounds tested, naproxen (d-2(6'-methoxy-2'-naphthyl)-propionic acid) proved the most active in animal tests, being some 55 times as potent as aspirin as an anti-inflammatory agent in standard tests and seven times as potent as aspirin as an analgesic (Roskowski, Rooks, Tomolonis, and Miller, 1971) . of 500 mg. naproxen was therapeutically effective, and that the drug was significantly better than placebo. To establish more precisely the place of naproxen in the treatment of rheumatoid arthritis and to compare its efficacy and tolerance with aspirin, a controlled comparative study become necessary and is the subject of this paper. Because early results confirmed that the drug was well tolerated, an additional open study included patients who could not tolerate other drugs.
Material and methods
Patients had definite or classical sero-positive RA and satisfied at least three of the following four criteria:
Six or more painful or tender joints;
Three or more joints with active synovitis; Morning stiffness lasting 45 min. or more; Erythrocyte sedimentation rate (ESR) not less than 28 mm. 1st hr (Westergren) All patients were on active therapy up to the start of the study. Other non-hormonal anti-inflammatory agents in use were withdrawn at the start of the trial, but the fifteen patients who were taking a small dose of corticosteroid, not exceeding 7-5 mg. prednisolone, five having maintenance gold salts, and three taking an anti-malarial drug continued these throughout the study in the same dosage.
4 weeks. Patients were seen fortnightly, so that two assessments were planned for each treatment period. These assessments also provided an opportunity to switch patients at an earlier stage to the second drug or to withdraw patients from the trial if the need arose. The dose of naproxen was 200 mg. in the morning, 300 mg. at night and of aspirin 1 g. four times daily.
Identical placebo capsules were used to make the programme up to three capsules four times daily. Laboratory investigations A full blood count, ESR, liver function tests, blood electrolytes, urea, glucose, urinary glucose, and protein were done on admission and at the end of each treatment period. Protein-bound iodine, T4, lipids, and occult bloods were measured in some patients. No significant changes occurred in haematological or biochemical indices with the exception of some changes in T4 and one elevated S.G.P.T. in patients taking aspirin, the latter returning to normal after changing to naproxen. Patients in whom any parameter was inadvertently not recorded at the end of one or other treatment period were excluded from the analysis as were two who reverted to pre-trial therapy on their own accord before a follow-up visit (one taking aspirin, the other naproxen). One copy of each recording form was returned to Syntex Pharmaceuticals Limited and results were analysed using an I.B.M. 360/65 computer.
Results
Fifty patients were enrolled in the study. Although no stratification was arranged of the groups receiving each drug first, the groups were in fact closely similar (Table II) . The longer duration of disease in the aspirin-first group was mainly due to three patients who had had rheumatoid arthritis for over 20 yrs, but the difference is not statistically significant. Of all parameters tested only grip strength (right) showed any significant difference, patients receiving naproxen first having weaker grip.
Of the fifty patients, six were withdrawn during the first 4 wks of the study (i.e. without experiencing both drugs). Three were switched to the second drug after 2 wks. Five of the six withdrawals and all three premature changes occurred during the aspirin-first phase, the difference being statistically significant (P <0-02 (Table III) ). Table IV shows the reasons for withdrawal in both phases of the study. Four patients in total withdrew on naproxen and twelve on aspirin, a significant difference (P <0 029) which was largely due to the high number of withdrawals for dyspepsia on aspirin (8), compared with none on naproxen (P <0-004).
An analysis was made to identify any differences at the time of admission between the patients who withdrew from the study and those who did not. The former differed in three parameters-morning stiffness, which was less by In addition to the significant responses to therapy shown by the total group, this sub-group demonstrated improvement in grip strength (left and right) with both drugs, but significant improvement in morning stiffness and ESR only with aspirin. In this group no significant differences were found between naproxen and aspirin in any parameter, including ESR, indicating equivalent efficacy of both drugs in this aspirin-tolerant sub-group.
Side-effects Table VII lists the side-effects thought by the investigator to be drug-related. Predictably, aspirin was associated with a high incidence of gastrointestinal upsets, these accounting for 31 of the 55 complaints. By contrast, the corresponding figures in the naproxen group were three and seventeen. Dizziness, tinnitus, and disturbance of hearing occurred more frequently during the aspirin periods. The overall incidence of side-effects was significantly less with naproxen (P <0-001), whether considered in terms of patient visits with complaints or numbers of patients complaining. Perhaps surprisingly, this held true even for the aspirin-tolerant sub-group in whom fewer side-effects might have been expected. 1 (1) 1 (1) 1 (1) 3 (3) 1 (1) 2 (2) 1 (1) 'Tolerant' patients-naproxen v. aspirin-P <0-001 (visits), P <0 01 (patients).
accepted, the large number of strongly positive tests with aspirin compared to the small number with naproxen (Table VIII) correlates well with the relative incidence of dyspepsia. Results 49 patients were included in this study, sixteen from the double-blind cross-over study, 27 who had had side-effects while taking other drugs (24 having dyspepsia), and six who had found previous therapy ineffective. Seven patients had proven peptic ulceration, probably related to non-hormonal antiinflammatory agents used previously. There were sixteen men and 33 women, the mean age was 57*8 ± 10-5 yrs, duration of disease 123A4 (range 6 mths to 32 yrs). All patients satisfied the criteria of disease activity required for admission to the doubleblind study, except that three were sero-negative, one of whom, together with a further five patients, satisfied only two of the four disease activity criteria.
The responses to previous treatment are shown in Table X . All drug regimes in the 'difficult to treat' group had produced substantial numbers of gastrointestinal (and occasionally other) side-effects, ranging from dyspepsia and ulceration to haematemesis and/or melaena.
The duration of the treatment with naproxen among these patients, shown in Table XI , varied from less than 1 mth to 9 mths. Eleven patients have withdrawn for the reasons indicated in Table XIII . Side-effects Table XIII shows the incidence of side-effects One of the seven patients with an unequivocal attributed to naproxen. With the exception of history of peptic ulceration was withdrawn for sleeplessness, all such effects occurred in patients recurrent dyspepsia.
with a previous history of dyspepsia. Investigators were sceptical about the relation of some complaints Efficacy to the drug. These included mild dyspepsia, insomnia, Symptomatic assessment of long-term efficacy in a constipation (two examples of each mentioned at a disease prone to variation in severity and sporadic single visit), and dry mouth (one example). remission is difficult. Nonetheless an attempt was Two patients developed a rash within a week of made to assess patients in this study in two ways: starting naproxen which cleared when naproxen was t One additional patient withdrew for a rash, and two for dyspepsia, not considered drug-related by the investigator.
Total number of withdrawals eleven, of which eight were considered to be drug-related.
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Stools for estimation of occult blood were collected in twelve patients on admission to the study. Eight of these were positive, two +++ or more. During treatment forty specimens were collected, of which two were positive +++ or more, one of these being from a patient with a positive admission test.
Discussion
The results of these two studies clearly demonstrate the efficacy of naproxen in the treatment of rheumatoid arthritis, its effect being both anti-inflammatory as assessed by changes in PIP joint swelling (Boardman and Hart, 1967) and analgesic. Its efficacy was comparable to that of 4 g. aspirin, both in the total group of patients and in a sub-group selected on the grounds of ability to tolerate both drugs under test. Side-effects and withdrawals were common with aspirin during the double-blind study, but significantly less frequent with naproxen. Interestingly, even the selected 'aspirin-tolerant' sub-group still showed a significant difference in side-effects and this high degree of tolerance of naproxen was confirmed in the open study, particularly in patients with multiple intolerance of other anti-rheumatic agents.
Previous publications concerned with the design and interpretation of clinical trials of new nonhormonal anti-inflammatory agents have identified a number of possible pitfalls. Thus, Donnelly, Lloyd, and Campbell (1967) emphasized the importance of placebo effect in the first part of a double-blind cross-over trial, and the possibility of carry-over from the first phase to the second. The latter was searched for in the study by several statistical procedures with negative results. The placebo effect is more difficult to detect in comparisons of two active drugs but the consensus of opinion seems to be that even where this is present it does not last longer than 7 days (Lussier and others, 1973) . The treatment periods in this study lasted 4 weeks. Mason, Barnardo, Fox, and Weatherall (1967) identified possible sources of bias as subjective improvement regardless of treatment, spurious improvement due to drop-out of the most severely ill, and the contribution of the physician to the assessment. The second of these was answered in this study by analysis of the sub-group undergoing the full trial, and by the analysis of admission parameters of the patients dropping out, which showed them to have lesser disease activity. The third possible bias was largely eliminated by the assessment of all patients in any one centre by the same physician, and by the rigid admission criteria which ensured that the patients had active disease.
Detection of subjective improvement regardless of treatment is difficult where two active drugs are being compared and when patients are seen and examined every 2 weeks. However, two relatively objective measures, total PIP measure and grip strength, improved during the study. Thus the design of the double-blind trial goes a considerable way towards avoiding the pitfalls of drug assessment.
These considerations are even more pertinent in open studies in which there is a greater potential for showing a beneficial effect. Although tolerance to the test drug in patients intolerant of another drug can be verified completely only if the patient is challenged on a double-blind basis with the drug which produced side-effects, in this open study it was not possible ethically to confirm the superiority of the new drug by reintroducing the poorly tolerated drug because ofthe risk ofpotentially serious hazards. However, patients who have had side-effects with one or more non-hormonal anti-inflammatory agents may be more likely to report these when taking a new agent, particularly when investigators are careful, as they were in this study, not to 'oversell' the latter.
It was gratifying that the majority of patients receiving naproxen either improved or remained as well controlled as on entry to the open study. The incidence of side-effects was very low. Summary 83 patients were studied in two trials of naproxen (d -2(6' -methoxy -2' -naphthyl) -propionic acid), a new non-hormonal anti-inflammatory agent.
In the first study, a double-blind cross-over trial of two consecutive 4-wk periods, naproxen and aspirin, in total daily doses of 500 mg. and 4 g. respectively, were compared in fifty patients with classical or definite rheumatoid arthritis. The two drugs proved to be equally effective in controlling this disease as assessed by objective and subjective parameters. Naproxen, however, was much better tolerated, and, in particular, was associated with much less dyspepsia or evidence of gastrointestinal bleeding.
The second study, which was of open design and indefinite duration, included sixteen patients from the double-blind study who had preferred naproxen (because of equal or greater relief compared with aspirin or better tolerance), and 33 patients who had found other drugs less satisfactory, either because of inadequate control (6), or of major adverse effectsgastrointestinal (24) with overt bleeding, and radiographically established peptic ulceration (7). Despite the inclusion of many 'difficult to treat' patients, only three of the 27 had persistent adverse reactions to naproxen, and evidence of faecal blood loss was insignificant. Clinical improvement occurred in the open trial in 63 per cent., while 25 per cent. remained unchanged.
Comprehensive laboratory tests in both trials revealed no significant deviation from normal which could be attributed to naproxen.
Thus naproxen in a daily dose of 500 mg. appears to be a safe anti-inflammatory and analgesic drug equal in effect to 4 g. aspirin in the treatment of rheumatoid arthritis and is often better tolerated. In addition, patients appreciate the need for only two daily doses. No hazardous adverse effects have been noted to date.
We thank our colleagues, nurses, physiotherapists, and secretaries for their help, and our patients for their willing co-operation. Mr I think one should try and get some idea of the optimum dose for each patient before comparing drugs. DR. HILARY HILL Fourteen patients continued to take a small dose of corticosteroid, 4 gold salts and 2 antimalarials. The only other drug in a patient with epilepsy taken throughout the study was mysoline. Some patients took hypnotics including barbiturates, but not necessarily on every night. DR. GUMPEL The problems that are experienced with fixed dosages of drugs that Dr. Holt mentioned applies equally to the naproxen and the aspirin in the study and is just one of the difficulties in any double-blind trial. PROF. V. WRIGHT (Leeds) That is right. I accept what Dr. Holt is saying, but we undertake a trial as a basis for further therapy, and practitioners will base this on the optimum dose. Now I am sure this particular trial was not undertaken without pilot studies in which the optimum dose was found, but once you have found what you think is the optimum dose by pilot studies, it would seem to me to be the most realistic to conduct a trial with a given dose that practitioners will use in the days that lie ahead. DR. A. ST. J. DIXON (Bath) I do take your point and I think that it is very nice to be here and to listen to reports of clinical trials done on a statistically controlled basis. In many countries abroad one would not have that privilege, and new drugs would be introduced without proper control.
